• Consensus Rating: Buy
  • Consensus Price Target: $4.50
  • Forecasted Upside: 89.87 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.37
▲ +0.03 (1.28%)

This chart shows the closing price for GERN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Geron Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GERN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GERN

Analyst Price Target is $4.50
▲ +89.87% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Geron in the last 3 months. The average price target is $4.50, with a high forecast of $7.00 and a low forecast of $3.00. The average price target represents a 89.87% upside from the last price of $2.37.

This chart shows the closing price for GERN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Geron. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2022Needham & Company LLCBoost TargetBuy$2.00 ➝ $3.00Low
7/28/2022B. RileyReiterated RatingBuy$4.00Low
7/11/2022HC WainwrightReiterated RatingBuy$7.00N/A
3/11/2022B. RileyReiterated RatingBuyHigh
3/11/2022HC WainwrightReiterated RatingBuy$7.00Medium
11/16/2021HC WainwrightReiterated RatingBuy$7.00Medium
11/1/2021Robert W. BairdInitiated CoverageOutperform$4.00High
10/13/2021HC WainwrightReiterated RatingBuy$7.00High
7/26/2021Cantor FitzgeraldReiterated RatingOverweightHigh
4/8/2021HC WainwrightReiterated RatingBuyHigh
2/17/2021B. RileyReiterated RatingBuyHigh
10/14/2020B. RileyReiterated RatingBuyLow
8/26/2020HC WainwrightBoost TargetPositive ➝ Buy$4.00 ➝ $7.00High
8/3/2020Stifel NicolausInitiated CoverageBuy$3.00High
6/17/2020Needham & Company LLCReiterated RatingBuy$3.00High
6/1/2020Cantor FitzgeraldBoost TargetOverweight$3.00 ➝ $4.00Low
5/29/2020B. RileyBoost TargetBuy$3.50 ➝ $4.00High
4/3/2020BTIG ResearchLower TargetBuy$4.00 ➝ $3.00High
3/17/2020B. RileyLower TargetBuy$4.00 ➝ $3.50High
3/13/2020Needham & Company LLCReiterated RatingBuy$3.00High
12/23/2019Needham & Company LLCReiterated RatingBuy$3.00Low
11/27/2019HC WainwrightReiterated RatingBuy$4.00Medium
11/19/2019B. RileyInitiated CoverageBuy$4.00High
11/7/2019Needham & Company LLCReiterated RatingBuy$3.00Medium
9/3/2019HC WainwrightInitiated CoverageBuy$4.00 ➝ $4.00High
8/15/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$4.00 ➝ $4.00High
6/28/2019B. RileyBoost TargetBuy$3.25 ➝ $4.50High
4/9/2019Needham & Company LLCUpgradeHold ➝ Buy$3.00High
2/12/2019BTIG ResearchInitiated CoverageBuy$4.00 ➝ $4.00High
1/31/2019B. RileyUpgradeNeutral ➝ Buy$1.50 ➝ $3.25Low
10/2/2018B. RileyDowngradeBuy ➝ Neutral$5.75 ➝ $1.50High
9/27/2018S&P Equity ResearchLower Target$2.32 ➝ $1.80High
7/5/2018FBR & Co.Initiated CoverageBuyHigh
7/5/2018B. RileyInitiated CoverageBuy$5.75High
3/19/2018Piper Jaffray CompaniesReiterated RatingBuy$7.00High
3/18/2018Stifel NicolausBoost TargetHold ➝ Hold$2.50 ➝ $4.00High
11/3/2017Needham & Company LLCReiterated RatingHoldN/A
11/3/2017Stifel NicolausReiterated RatingHold$2.50N/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/7/2022
  • 5 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/6/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/5/2022
  • 3 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/5/2022
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/4/2022
  • 9 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
9/3/2022
  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Geron logo
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $2.37
Low: $2.31
High: $2.42

50 Day Range

MA: $2.38
Low: $1.86
High: $2.94

52 Week Range

Now: $2.37
Low: $0.99
High: $3.06

Volume

2,167,020 shs

Average Volume

2,893,730 shs

Market Capitalization

$895.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Geron?

The following Wall Street research analysts have issued stock ratings on Geron in the last twelve months: B. Riley, HC Wainwright, Needham & Company LLC, Robert W. Baird, and StockNews.com.
View the latest analyst ratings for GERN.

What is the current price target for Geron?

4 Wall Street analysts have set twelve-month price targets for Geron in the last year. Their average twelve-month price target is $4.50, suggesting a possible upside of 89.9%. HC Wainwright has the highest price target set, predicting GERN will reach $7.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $3.00 for Geron in the next year.
View the latest price targets for GERN.

What is the current consensus analyst rating for Geron?

Geron currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GERN will outperform the market and that investors should add to their positions of Geron.
View the latest ratings for GERN.

What other companies compete with Geron?

How do I contact Geron's investor relations team?

Geron's physical mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company's listed phone number is (650) 473-7700 and its investor relations email address is [email protected] The official website for Geron is www.geron.com. Learn More about contacing Geron investor relations.